Page 5,466«..1020..5,4655,4665,4675,468..5,4805,490..»

Arthritis Stem Cell Treatment for Dogs Leads Pack

Posted: Published on April 9th, 2013

A couple of years ago, Brad Perry's dogs started having joint problems. Cowboy, the golden retriever, developed a severe case of arthritis, while Mr. Jones, the mutt, tore the ligaments in both of his knees during some overenthusiastic play. "It was so sad. They wouldn't even come to the door to greet me they were in so much pain. It just broke my heart," recalled Perry, a tractor-trailer driver from Alexandria, Ky. Perry gave the dogs all sorts of medications, but nothing worked, and he knew such medications could result in kidney and liver damage. The dogs' suffering became so great, Perry considered putting the pets down. But late last year he heard about a veterinarian in his area who performed stem cell therapy on dogs to regenerate and repair their joints and figured it was worth a try. Cowboy underwent the procedure first. Mr. Jones followed a few months later. Perry said that within 10 days of receiving treatment the dogs were like puppies again, chasing his kids, running around in the park and swimming in the lake. The treatment Perry's dogs received was developed by MediVet America of Lexington, Ky., one of several companies that sell equipment and … Continue reading →

Comments Off on Arthritis Stem Cell Treatment for Dogs Leads Pack

BIND Therapeutics Presents Positive Clinical Data at the AACR 2013 Annual Meeting for Lead Accurin Candidate, BIND-014 …

Posted: Published on April 9th, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the companys lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research (AACR) 2013 Annual Meeting. Clinical investigators presented the Phase 1 results with BIND-014, its targeted docetaxel Accurin, in 28 heavily-pretreated patients with advanced or metastatic solid tumors. In the study, BIND-014 was shown to be generally safe and well-tolerated at the established maximum tolerated dose of 60 mg/m2 and showed encouraging signs of anti-tumor activity including one complete response, three partial responses and five patients with stable disease lasting at least four cycles (> 12 weeks). In addition, the pharmacokinetic (PK) profile of BIND-014 was substantially different from the published PK of conventional docetaxel. This Phase 1 trial has successfully established the safety and tolerability profile and maximum tolerated dose of BIND-014 in patients with advanced or metastatic solid tumor cancers, commented Daniel D. Von Hoff, M.D., F.A.C.P., Principal Investigator for the study and Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) and the Scottsdale Clinical … Continue reading →

Comments Off on BIND Therapeutics Presents Positive Clinical Data at the AACR 2013 Annual Meeting for Lead Accurin Candidate, BIND-014 …

BUSINESS WIRE: Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics …

Posted: Published on April 9th, 2013

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. o Launch expected in April 2013 PARIS & MONTREAL --(BUSINESS WIRE)-- 09.04.2013 -- Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) today announced that Health Canada has granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market Dysport for use in aesthetic medicine in Canada. Launch is expected in April 2013. Pierre Boulud, Executive Vice-President, Corporate Strategy, Ipsen's group, stated: "This presentation is in line with Ipsen's commitment to an increased focus and investment behind Dysport and to extend its geographical footprint. After its approval in 2009 in the United States, Dysportwill now be available in Canada for the treatment of glabellar lines." About Dysport The active substance in Dysport is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm. It was initially developed to treat motor disorders and various forms of … Continue reading →

Posted in Aesthetic Medicine | Comments Off on BUSINESS WIRE: Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics …

BUSINESS WIRE: Ipsen's DysportR approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics …

Posted: Published on April 9th, 2013

BUSINESS WIRE: Ipsen's DysportR approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada 09.04.2013, 07:30:03 MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. o Launch expected in April 2013 PARIS & MONTREAL --(BUSINESS WIRE)-- 09.04.2013 -- Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) today announced that Health Canada has granted a marketing authorization for DysportR (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market DysportR for use in aesthetic medicine in Canada. Launch is expected in April 2013. Pierre Boulud, Executive Vice-President, Corporate Strategy, Ipsen's group, stated: "This presentation is in line with Ipsen's commitment to an increased focus and investment behind DysportR and to extend its geographical footprint. After its approval in 2009 in the United States, DysportRwill now be available in Canada for the treatment of glabellar lines." About DysportR The active substance in DysportR is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted … Continue reading →

Posted in Aesthetic Medicine | Comments Off on BUSINESS WIRE: Ipsen's DysportR approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics …

Ipsen: Dysport Approved For Use In Aesthetic Medicine In Canada – Quick Facts

Posted: Published on April 9th, 2013

By RTT News, April 09, 2013, 01:46:00 AM EDT (RTTNews.com) - Ipsen (IPSEY.PK) said that it was granted a marketing authorization for Dysport by Health Canada for the temporary improvement in the appearance of moderate to severe frown lines in adult patients younger than 65 years of age. Medicis Aesthetics Canada, an unit of Valeant Pharmaceuticals, would market Dysport for use in aesthetic medicine in Canada. The launch may take place in April 2013. The company said in a statement: "This presentation is in line with Ipsen's commitment to an increased focus and investment behind Dysport and to extend its geographical footprint. After its approval in 2009 in the United States, Dysport will now be available in Canada for the treatment of glabellar lines." The active substance in Dysport is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm. For comments and feedback: contact editorial@rttnews.com http://www.rttnews.com More here: Ipsen: Dysport Approved For Use In Aesthetic Medicine In Canada - Quick Facts … Continue reading →

Posted in Aesthetic Medicine | Comments Off on Ipsen: Dysport Approved For Use In Aesthetic Medicine In Canada – Quick Facts

Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada

Posted: Published on April 9th, 2013

PARIS & MONTREAL--(BUSINESS WIRE)-- Regulatory News: Ipsen (IPN.PA) (Euronext: IPN, ADR: IPSEY) today announced that Health Canada has granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market Dysport for use in aesthetic medicine in Canada. Launch is expected in April 2013. Pierre Boulud, Executive Vice-President, Corporate Strategy, Ipsens group, stated: This presentation is in line with Ipsens commitment to an increased focus and investment behind Dysport and to extend its geographical footprint. After its approval in 2009 in the United States, Dysportwill now be available in Canada for the treatment of glabellar lines. About Dysport The active substance in Dysport is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm. It was initially developed to treat motor disorders and various forms of muscular spasticity, including cervical dystonia (or spasmodic torticollis, a chronic condition in which the neck is twisted or deviated), spasticity of the upper/lower … Continue reading →

Posted in Aesthetic Medicine | Comments Off on Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada

Rejuv Medical Announces Stem Cell Treatments Now Available

Posted: Published on April 9th, 2013

Rejuv Medical, a sports medicine company based out of Minnesota, is now offering stem cell treatments to the companys clientele. Minnesota (PRWEB) April 08, 2013 Our stem cell treatments are on the cutting edge of changing how sports injuries are treated. Surgery should always be the last option and our stem cell treatments are making this theory more of a reality, said J.R. Burgess of Rejuv Medical. Our company has launched a version of advanced stem cell and platelete procedures from Regenexx. There are two types of procedures, the Same Day(SD) Stem Cell Treatments and the Stem Cell Plasma(SCP) Procedure. Rejuv Medical is utilizing the same stem cell treatments that were featured on The Doctors TV show. Not everyone is going to be a candidate, but these services are worth the consideration, continued Burgess. Rejuv Medical wants people to know, especially those with sports injuries, that stem cell treatments are available in the United States. Many people travel to Rejuv Medical in Minnesota to help them get back in the game and on with their lives. Rejuv Medicals Twitter account is: https://twitter.com/RejuvMedical Rejuv Medical specializes in Orthopedic and Sports Medicine, weight loss and fitness, anti-aging procedures, and is dedicated to … Continue reading →

Posted in Stem Cell Treatments | Comments Off on Rejuv Medical Announces Stem Cell Treatments Now Available

StemCells, Inc. Closes $10 Million Debt Financing

Posted: Published on April 9th, 2013

NEWARK, Calif., April 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that it has closed a $10 million debt financing from Silicon Valley Bank (SVB). The loan funds will be used for general corporate purposes, and increase the Company's December 31, 2013 pro forma cash balance to $34.4 million. This total also includes $2.0 million in net proceeds received subsequent to the end of the year from the exercise of warrants and the sale of shares of common stock. "We are pleased to have secured this loan from Silicon Valley Bank," said Martin McGlynn, President and CEO of StemCells, Inc. "These funds will extend our cash runway and provide us with increased financial flexibility. Sophisticated institutions like SVB are very careful and thoughtful when making their lending decisions, and we appreciate the confidence shown by SVB in our company." The loan has a three-year term and interest will accrue at 6% per annum. For the first six months, payments will be interest only and then the loan will be amortized over 30 months. In addition, there will be a final payment at the end of the term equal to $1 million. In connection with the debt financing, the … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on StemCells, Inc. Closes $10 Million Debt Financing

I Met A Survivor – Video

Posted: Published on April 9th, 2013

I Met A Survivor Ok leave it up to me, talking to strangers. I met a breast cancer survivor in the elevator today. Why did that lady have me almost in tears in public? By: SomePisces Chic … Continue reading →

Comments Off on I Met A Survivor – Video

BrainStorm Partners With Dana-Farber for NurOwn(TM) Production in Phase II ALS Clinical Trial

Posted: Published on April 9th, 2013

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - Apr 8, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dana-Farber Cancer Institute ("Dana-Farber") has entered into an agreement to provide cGMP-compliant clean room facilities for production of BrainStorm's NurOwn stem cell candidate during its upcoming Phase II ALS trial in the USA. The Company's Phase II trial, to be launched in the second half of 2013 pending FDA approval, will be conducted at Massachusetts General Hospital ("MGH"), the University of Massachusetts ("UMass") Hospital and the Mayo Clinic. The Connell and O'Reilly Cell Manipulation Core Facility at Dana-Farber will produce NurOwn for the MGH and UMass Hospital clinical sites. "We are pleased to begin this work that could be of great value to ALS patients," said Dr. Jerome Ritz, Director of the Connell and O'Reilly Cell Manipulation Core Facility at Dana-Farber and Professor of Medicine at Harvard Medical School. "This is exactly the kind of service that the facility was set up to provide. We appreciate the opportunity to work closely with BrainStorm and colleagues at MGH and UMass to advance cell therapy solutions for difficult diseases." "Today's announcement … Continue reading →

Comments Off on BrainStorm Partners With Dana-Farber for NurOwn(TM) Production in Phase II ALS Clinical Trial

Page 5,466«..1020..5,4655,4665,4675,468..5,4805,490..»